Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • bristol-myers-squibb

    Tag: ​bristol myers squibb

    You Searched For "bristol-myers-squibb"
    Cancer tech Patent Infringment: Gilead Sciences told to pay 1.2 billion dollars to Bristol-Myers Squibb

    Cancer tech Patent Infringment: Gilead Sciences told to pay 1.2 billion dollars to Bristol-Myers Squibb

    Medical Dialogues Bureau11 April 2020 1:56 PM IST
    USA: A federal judge increased to $1.2 billion the damages that Gilead Sciences Inc must pay to Bristol-Myers Squibb Co in a patent infringement...
    Bristol Myers Squibb, bluebird bio announce submission of BLA for Myeloma Drug to USFDA

    Bristol Myers Squibb, bluebird bio announce submission of BLA for Myeloma Drug to USFDA

    Medical Dialogues Bureau4 April 2020 2:09 PM IST
    BCMA is a protein that is nearly universally expressed on cancer cells in multiple myeloma, making it an important potential target for the treatment...
    More drugmakers including Gilead, Biogen, BMS to hike US prices for 50 drugs

    More drugmakers including Gilead, Biogen, BMS to hike US prices for 50 drugs

    Medical Dialogues Bureau2 Jan 2020 2:48 PM IST
    New Delhi: Drugmakers including Bristol-Myers Squibb Co (BMY.N), Gilead Sciences Inc (GILD.O), and Biogen Inc (BIIB.O) hiked U.S. list prices on more...
    FIRST: Mylan, Micro Labs get USFDA nod for generic version of blood thinner Eliquis

    FIRST: Mylan, Micro Labs get USFDA nod for generic version of blood thinner Eliquis

    Medical Dialogues Bureau24 Dec 2019 9:45 AM IST
    Sales of Eliquis, which Bristol-Myers co-developed with Pfizer, rose 22% to $1.93 billion and made up about 30% of the Bristol-Myers' total revenues...
    Bristol-Myers Opdivo, Yervoy show promise in lung cancer trial

    Bristol-Myers Opdivo, Yervoy show promise in lung cancer trial

    Medical Dialogues Bureau3 Nov 2019 9:00 AM IST
    Bristol-Myers Squibb said its therapies when administered alongside two courses of chemotherapy demonstrated superior overall survival compared to...
    Apixaban Patent: Natco gets HC relief for its upcoming medicine Apigat

    Apixaban Patent: Natco gets HC relief for its upcoming medicine Apigat

    Farhat Nasim26 July 2019 3:00 PM IST
    NEW DELHI: Days after ending a patent row over its cancer drug Regonat with Bayer, drugmaker, Natco Pharma is reported to have now been embroiled in a...
    Abbvie finalizes deal to buy Botox maker Allergan for $63 billion

    Abbvie finalizes deal to buy Botox maker Allergan for $63 billion

    Medical Dialogues Bureau26 Jun 2019 10:00 AM IST
    A note from Moody's affirmed Abbvie's debt rating, saying a plan to reduce debt through existing blockbusters like AbbVie's Humira and Imbruvica and...
    Bristol-Myers to sell blockbuster Otezla for its $74 billion merger with Celgene

    Bristol-Myers to sell blockbuster Otezla for its $74 billion merger with Celgene

    Medical Dialogues Bureau26 Jun 2019 9:00 AM IST
    Bristol-Myers announced its plans to buy Celgene in a cash-and-stock deal in early January to bring together the companies that specialize in oncology...
    Merck wins USFDA nod for blockbuster drug Keytruda to treat head, neck cancer

    Merck wins USFDA nod for blockbuster drug Keytruda to treat head, neck cancer

    Medical Dialogues Bureau12 Jun 2019 9:50 AM IST
    The approval is based on results from a late-stage trial, where Keytruda showed a significant improvement in overall survival in cancer patients,...
    CDSCO Committee rejects proposal for additional Indications of Dapaglofizin

    CDSCO Committee rejects proposal for additional Indications of Dapaglofizin

    Meghna A Singhania5 May 2019 12:52 PM IST
    New Delhi: British-Swedish multinational drugmaker, AstraZeneca's stride to win approval from the Indian drug regulators for the additional...
    Vaccine and blood thinner help drive Pfizer to quarterly earnings beat

    Vaccine and blood thinner help drive Pfizer to quarterly earnings beat

    Medical Dialogues Bureau1 May 2019 12:07 PM IST
    Pfizer Inc on Tuesday reported a first-quarter profit that beat Wall Street estimates and slightly raised its 2019 earnings forecast, as the company...
    Pfizer quarterly profit in line, touts pipeline of future products

    Pfizer quarterly profit in line, touts pipeline of future products

    Medical Dialogues Bureau31 Jan 2019 9:05 AM IST
    On a call with analysts, new Chief Executive Albert Bourla said Pfizer had "the best pipeline in our history," and predicted that the company would...
    Next

    Popular Stories

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok